PierianDx

PierianDx Announces Multi-Year Agreement with Illumina

Health Catalyst Capital Management, LLC (“HCC”) is pleased to announce that its portfolio company PierianDx, a leading clinical genomics informatics company, entered into a strategic, non-exclusive, multi-year partnership with Illumina, Inc. (ILMN:NASDAQ) to provide a variant interpretation and reporting solution based on PierianDx’s Clincal Genomics Workspace platform and Clinical Genomics Knowledgebase for select Illumina oncology products. Under the agreement, PierianDx Read more about PierianDx Announces Multi-Year Agreement with Illumina[…]